Acerus Provides Business Update on NATESTO®

36

TORONTO–(BUSINESS WIRE)–Acerus Pharmaceuticals Corporation (TSX: ASP, OTCQB: ASPCF) (“Acerus” or the “Company”) announced today an update relative to the Company’s NATESTO® business. The Company announced that Hyundai Pharm Co., Ltd. (“Hyundai”) has officially launched the commercialization of NATESTO® in South Korea. Hyundai, Acerus’ licensee for South Korea, officially launched NATESTO® at the Korean Symposium on Sexual Medicine and Andrology (KSSMA). Hyundai plans to continue to ramp up ….

 

 

http://www.businesswire.com/news/home/20190710005036/en/Acerus-Business-Update-NATESTO%C2%AE